Health Technology Assessment (HTA)
Health technology assessment (HTA) is a multidisciplinary process that systematically evaluates the properties and effects of a health technology — a drug, device, procedure, diagnostic, or organisational intervention — to inform decisions about its value and place in a health system. It draws on clinical effectiveness evidence and economic evaluation, and increasingly on ethical, social, legal, and organisational considerations, to support policy and reimbursement choices.
Definition
HTA is the systematic, multidisciplinary evaluation of the medical, economic, social, and ethical implications of the development, diffusion, and use of a health technology, conducted to inform policy and decision-making.
Scope
This area orients the reader to HTA as a field within evidence-based practice and health policy: what HTA is for, the domains it assesses, and how its analytic building blocks fit together. It links to detailed topic entries on the HTA process and framework, cost-effectiveness analysis, budget impact analysis, and the quality-adjusted life year. It is a reference overview and does not provide reimbursement, pricing, or treatment recommendations.
Sub-topics
Core questions
- Does the technology work, and how does it compare with existing alternatives (relative effectiveness)?
- What does the technology cost, and what health gains does it buy relative to those costs?
- What would adopting it mean for budgets, services, and equity in a given health system?
- What ethical, legal, social, and organisational considerations bear on its use?
Key concepts
- Health technology
- Relative (comparative) effectiveness
- Economic evaluation
- Assessment domains (clinical, economic, ethical, social, legal, organisational)
- Evidence synthesis and the EUnetHTA Core Model
- Decision and reimbursement context
- Distinction between assessment and appraisal
Mechanisms
An HTA typically defines a policy question and comparator, synthesises evidence on clinical effectiveness and safety, conducts an economic evaluation (often cost-effectiveness and budget impact analysis), and considers ethical, social, legal, and organisational domains. Structured frameworks such as the EUnetHTA HTA Core Model organise these domains so that assessments are transparent and transferable across settings. The product of the assessment then feeds an appraisal step, in which a decision-making body weighs the evidence against contextual values to reach a recommendation.
Clinical relevance
HTA shapes which technologies become available within health systems and on what terms, so understanding it helps clinicians and researchers interpret coverage and reimbursement decisions. It is a reference field describing how evidence on value is generated and used at the system level, not a guide to individual diagnosis or treatment.
Evidence & guidelines
HTA practice is anchored by international methods guidance: the EUnetHTA Core Model standardised assessment domains (Lampe et al., 2009); the Second US Panel on Cost-Effectiveness in Health and Medicine updated recommendations for conducting and reporting cost-effectiveness analyses (Sanders et al., 2016); and standard methods texts such as Drummond et al. (2015) codify economic evaluation. The internationally agreed definition of HTA was published by O'Rourke et al. (2020) on behalf of a joint INAHTA/HTAi working group.
History
HTA emerged in the 1970s as policymakers sought systematic ways to evaluate costly and rapidly diffusing medical technologies, with early activity in the United States and the founding of national agencies and the international network INAHTA. Over subsequent decades it spread internationally, embedded economic evaluation at its core, and developed shared methods and collaborative structures such as EUnetHTA. A consensus international definition was agreed in 2020, reflecting the field's maturation toward cross-border collaboration.
Debates
- How far should HTA extend beyond clinical and economic evidence?
- There is ongoing discussion about how systematically ethical, social, legal, and organisational domains should be assessed alongside effectiveness and cost-effectiveness, and how to weigh them in appraisal; frameworks like the Core Model formalise these domains but their use varies.
Key figures
- Michael Drummond
- Peter J. Neumann
- Wija Oortwijn
- Brian O'Rourke
Related topics
Seminal works
- orourke-2020
- lampe-2009
- sanders-2016
- drummond-2015
Frequently asked questions
- What is the difference between assessment and appraisal in HTA?
- Assessment is the analytic synthesis of evidence on a technology's effects and value; appraisal is the subsequent judgement step in which a decision body weighs that evidence against contextual values to reach a recommendation.
- Is HTA only about cost?
- No. Economic evaluation is central, but HTA also assesses clinical effectiveness and safety and considers ethical, social, legal, and organisational domains.